Adult Cystic Fybrosis Adult Cystic Fibrosis Conference, 2023

Pulmonary exacerbation rates after three years of Elexacaftor/Tezacaftor/Ivacaftor therapy in adults with cystic fibrosis and severe lung disease

Pulmonary exacerbation rates after three years of Elexacaftor/Tezacaftor/Ivacaftor therapy in adults with cystic fibrosis and severe lung disease